Clinical trial
A Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma as Second-line or Salvage Chemotherapy
NCT04503967 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma as Second-line or Salvage Chemotherapy
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2020
- Completion date
- August 1, 2021
- Enrollment
- 48 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
esophageal squamous cell carcinoma, gastric adenocarcinoma